27 Oct, 2020
New study to test potential novel treatment for ulcerative colitis
Sano Genetics is supporting a study investigating the efficacy of a potential breakthrough treatment.
This study will enable participants to access medical professionals and potentially have the opportunity to determine whether a new once-daily oral investigational drug may provide an effective treatment for ulcerative colitis
What is ulcerative colitis?
Ulcerative colitis is an irritable bowel disease (IBD) which affects the large intestine, causing painful inflammation of the colon and rectum. Small ulcers can develop on the colon's lining, with patience experiencing stomach pain and debilitating side-effects.
In 2017, 6.8 million cases of IBD were recorded globally and its prevalence continues to increase. Many people with ulcerative colitis find that their treatment is not effective, so identifying potential new, more effective drug treatments is vital for enhancing patient outcomes.
Who can participate in the study?
Individuals aged between 18-80 years old who have been diagnosed with ulcerative colitis for more than 3 months, have experienced treatment failure and who are not pregnant, breastfeeding or planning to get pregnant, are invited to sign-up to the CALDOSE-1 study via Sano’s patient platform.
Participation in the study will enable participants to access medical professionals and potentially have the opportunity to determine whether a new once-daily oral investigational drug may provide an effective treatment for UC.
Patrick Short, CEO of Sano Genetics, said: “We’re delighted to be able to help match patients from the Sano platform who want to join research to this exciting study, which has the potential to significantly improve treatment for patients with ulcerative colitis. Patient recruitment for clinical research can be challenging, and we are glad to see our model for patient-centric and data-driven research matchmaking being adopted by top biotechnology companies and CROs.”